Endo Buys Dava, Building In Generics
This article was originally published in The Pink Sheet Daily
The acquisitive specialty pharma will buy privately-held generics firm Dava Pharmaceuticals for $575 million in cash and potentially another $25 million based on the achievement of certain sales milestones.
You may also be interested in...
Former Valeant President De Silva joins Endo in the midst of a challenging year for the company, as two top-selling drugs face generic competition. De Silva will need to reenergize Endo and do so quickly if he is to maintain the early favor he appears to have won from investors.
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.